Academic Journal

PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China

Get it

Liu, Xiaoyu, Liu, Zhaoyun, Li, Chao, Song, Xiang, Wang, Xinzhao, Li, Sumei, Yu, Zhiyong

World Journal of Surgical Oncology. 21(1)

Saved in:

Bibliographic Details
Title	PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
Authors	Liu, Xiaoyu, Liu, Zhaoyun, Li, Chao, Song, Xiang, Wang, Xinzhao, Li, Sumei, Yu, Zhiyong
Source	World Journal of Surgical Oncology. 21(1)
This result is restricted to LU affiliated users only. Sign in or register for an institutional account to gain full access, if eligible.